FDA accepts Incyte's axatilimab application for priority review in chronic graft-versus-host disease treatment by August 28.
Incyte's (NASDAQ:INCY) application for its drug candidate axatilimab for chronic graft-versus-host disease treatment has been accepted by the FDA for priority review. The decision deadline is set for August 28. Axatilimab, developed with Syndax Pharmaceuticals, is being tested after at least two prior lines of systemic therapy. Positive results from the AGAVE-201 trial support the BLA.
February 27, 2024
5 Articles